vs
Side-by-side financial comparison of Expeditors International (EXPD) and Zoetis (ZTS). Click either name above to swap in a different company.
Expeditors International is the larger business by last-quarter revenue ($2.9B vs $2.4B, roughly 1.2× Zoetis). Zoetis runs the higher net margin — 25.3% vs 7.0%, a 18.2% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -3.3%). Zoetis produced more free cash flow last quarter ($732.0M vs $270.3M). Over the past eight quarters, Expeditors International's revenue compounded faster (13.8% CAGR vs 4.4%).
Expeditors International of Washington, Inc. is an American Fortune 500 service-based logistics company with headquarters in Bellevue, Washington. Expeditors generates highly optimized and customized supply chain solutions for clients with unified technology systems integrated through a global network of over 340+ locations in 100+ countries on six continents.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
EXPD vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9B | $2.4B |
| Net Profit | $200.7M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 8.8% | 31.9% |
| Net Margin | 7.0% | 25.3% |
| Revenue YoY | -3.3% | 3.0% |
| Net Profit YoY | -14.9% | 3.8% |
| EPS (diluted) | $1.50 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9B | $2.4B | ||
| Q3 25 | $2.9B | $2.4B | ||
| Q2 25 | $2.7B | $2.5B | ||
| Q1 25 | $2.7B | $2.2B | ||
| Q4 24 | $3.0B | $2.3B | ||
| Q3 24 | $3.0B | $2.4B | ||
| Q2 24 | $2.4B | $2.4B | ||
| Q1 24 | $2.2B | $2.2B |
| Q4 25 | $200.7M | $603.0M | ||
| Q3 25 | $222.3M | $721.0M | ||
| Q2 25 | $183.6M | $718.0M | ||
| Q1 25 | $203.8M | $631.0M | ||
| Q4 24 | $235.9M | $581.0M | ||
| Q3 24 | $229.6M | $682.0M | ||
| Q2 24 | $175.5M | $624.0M | ||
| Q1 24 | $169.2M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 8.8% | 31.9% | ||
| Q3 25 | 10.0% | 37.0% | ||
| Q2 25 | 9.3% | 36.7% | ||
| Q1 25 | 10.0% | 36.5% | ||
| Q4 24 | 10.2% | 31.6% | ||
| Q3 24 | 10.1% | 36.6% | ||
| Q2 24 | 9.2% | 33.0% | ||
| Q1 24 | 9.7% | 34.1% |
| Q4 25 | 7.0% | 25.3% | ||
| Q3 25 | 7.7% | 30.0% | ||
| Q2 25 | 6.9% | 29.2% | ||
| Q1 25 | 7.6% | 28.4% | ||
| Q4 24 | 8.0% | 25.1% | ||
| Q3 24 | 7.7% | 28.6% | ||
| Q2 24 | 7.2% | 26.4% | ||
| Q1 24 | 7.7% | 27.4% |
| Q4 25 | $1.50 | $1.37 | ||
| Q3 25 | $1.64 | $1.63 | ||
| Q2 25 | $1.34 | $1.61 | ||
| Q1 25 | $1.47 | $1.41 | ||
| Q4 24 | $1.68 | $1.29 | ||
| Q3 24 | $1.63 | $1.50 | ||
| Q2 24 | $1.24 | $1.37 | ||
| Q1 24 | $1.17 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.4B | $3.3B |
| Total Assets | $4.9B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.2B | $2.1B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.3B | $1.7B | ||
| Q4 24 | $1.1B | $2.0B | ||
| Q3 24 | $1.3B | $1.7B | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $1.4B | $2.0B |
| Q4 25 | $2.4B | $3.3B | ||
| Q3 25 | $2.3B | $5.4B | ||
| Q2 25 | $2.2B | $5.0B | ||
| Q1 25 | $2.3B | $4.7B | ||
| Q4 24 | $2.2B | $4.8B | ||
| Q3 24 | $2.4B | $5.2B | ||
| Q2 24 | $2.2B | $5.0B | ||
| Q1 24 | $2.2B | $5.1B |
| Q4 25 | $4.9B | $15.5B | ||
| Q3 25 | $4.8B | $15.2B | ||
| Q2 25 | $4.8B | $14.5B | ||
| Q1 25 | $4.8B | $14.1B | ||
| Q4 24 | $4.8B | $14.2B | ||
| Q3 24 | $5.2B | $14.4B | ||
| Q2 24 | $4.8B | $14.2B | ||
| Q1 24 | $4.5B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $283.3M | $893.0M |
| Free Cash FlowOCF − Capex | $270.3M | $732.0M |
| FCF MarginFCF / Revenue | 9.5% | 30.7% |
| Capex IntensityCapex / Revenue | 0.5% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.41× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $953.4M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $283.3M | $893.0M | ||
| Q3 25 | $201.4M | $938.0M | ||
| Q2 25 | $179.2M | $486.0M | ||
| Q1 25 | $342.6M | $587.0M | ||
| Q4 24 | $249.7M | $905.0M | ||
| Q3 24 | $90.0M | $951.0M | ||
| Q2 24 | $126.8M | $502.0M | ||
| Q1 24 | $256.9M | $595.0M |
| Q4 25 | $270.3M | $732.0M | ||
| Q3 25 | $190.3M | $805.0M | ||
| Q2 25 | $163.3M | $308.0M | ||
| Q1 25 | $329.5M | $438.0M | ||
| Q4 24 | $239.7M | $689.0M | ||
| Q3 24 | $77.7M | $784.0M | ||
| Q2 24 | $118.8M | $370.0M | ||
| Q1 24 | $246.7M | $455.0M |
| Q4 25 | 9.5% | 30.7% | ||
| Q3 25 | 6.6% | 33.5% | ||
| Q2 25 | 6.2% | 12.5% | ||
| Q1 25 | 12.4% | 19.7% | ||
| Q4 24 | 8.1% | 29.7% | ||
| Q3 24 | 2.6% | 32.8% | ||
| Q2 24 | 4.9% | 15.7% | ||
| Q1 24 | 11.2% | 20.8% |
| Q4 25 | 0.5% | 6.7% | ||
| Q3 25 | 0.4% | 5.5% | ||
| Q2 25 | 0.6% | 7.2% | ||
| Q1 25 | 0.5% | 6.7% | ||
| Q4 24 | 0.3% | 9.3% | ||
| Q3 24 | 0.4% | 7.0% | ||
| Q2 24 | 0.3% | 5.6% | ||
| Q1 24 | 0.5% | 6.4% |
| Q4 25 | 1.41× | 1.48× | ||
| Q3 25 | 0.91× | 1.30× | ||
| Q2 25 | 0.98× | 0.68× | ||
| Q1 25 | 1.68× | 0.93× | ||
| Q4 24 | 1.06× | 1.56× | ||
| Q3 24 | 0.39× | 1.39× | ||
| Q2 24 | 0.72× | 0.80× | ||
| Q1 24 | 1.52× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXPD
| Customs Brokerage And Other Services | $1.1B | 40% |
| Airfreight Services | $1.1B | 39% |
| Ocean Freight And Ocean Services | $611.4M | 21% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
